iLite ADCP Effector FcγRIIa Assay Ready Cells


The Eagle Bioscience’s iLite ADCP Effector FcγRIIa Assay Ready Cells are intended for quantifying biological activity induced by pathway activation of therapeutic antibody drugs in an ADCP mechanism of action (MOA) assay. The iLite ADCP Effector FcγRIIa Assay Ready Cells are for research use only and not to be used for diagnostic procedures.

iLite ADCP Effector FcγRIIa Assay Ready Cells

iLite ADCP Effector FcγRIIa Assay Ready Cells are Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite ADCP Effector FcγRIIa Assay Ready Cells are intended for:

  • Quantification of anti-HER2 ADCP activity.
  • Quantification of anti-CD20 ADCP activity.
  • Quantification of anti-mTNF-alpha ADCP activity.

Content: >250 μL of iLite Assay Ready Cells suspended in cryoprotective.

Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C or at lower temperature and are stable as supplied until the expiry date shown. Cells should be diluted and plated immediately after thawing.

For Research Use Only

Key Benefits of iLite Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Description

iLite ADCP Effector Assay Ready Cells are human-engineered cells optimized to express high levels of the low-affinity Fc receptor FcγRIIa (CD32), and the Firefly Luciferase (FL) reporter gene regulated by the NFAT response element. The ADCP reporter bioassay can be used to screen for biologics and other drugs via binding and activation of the FcγRIIa receptor. Normalization of cell counts, serum matrix effects, or lysis of the effector cells by the target cells is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor.

Related Products

iLite ADCC Target HER2 Negative Assay Ready Cells
iLite VEGF Assay Ready Cells
iLite G-CSF Assay Ready Cells


Product Manual

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Additional Information


Fc:FcγR interactions are highly involved in antitumor therapy and the mechanism of action is called antibody-dependent-cell-mediated phagocytosis (ADCP) which is mediated by the therapeutic antibody (1).While the antibody is binding to the tumor cell, the Fc portion of the antibody can engage the immune system to destroy the tumor by engagement of Fc receptors for IgG (FcγR) which are expressed by monocytes, macrophages, neutrophils and dendritic cells (1). This is resulting in internalization and degration of the pathogenic cell through phagosome acidification (1). Among the Fcγ-receptors (FcγRIIa, FcγRI and FcγRIIIa) the most important receptor involved in ADCP is FcγRIIa.

The first monoclonal antibody for treating cancer to be FDA approved was Rituximab which in part utilizes the antibody-dependent cellular cytotoxicity (ADCC) and ADCP mechanisms to destroy cancer cells expressing CD20 (2). The majority of therapeutic monoclonal antibodies are generating their effector cell functions by engaging their Fc part and thereby inducing ADCC and ADCP (2,3). Importantly, Fc-engineered antibodies with modulated effector functions to fit specific mechanisms of actions and cancer therapies are generated (3).


Discover the Benefits of iLite

Frequently Asked Questions

Frequently Asked Questions

Product Citations